Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Journal Health & Science : Gorontalo Journal Health and Science Community
Viqa Faiqah
Hematooncology Division Departement of Pediatrics, Hasanuddin University’s Faculty of Medicine/Wahidin Sudirohusodo Hospital, makassar, Indonesia
Health Professions Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
DIFFUSE LARGE CELL NON HODGKIN LYMPHOMA AT RETROBULBAR OCCULUS SINISTRA MASS Viqa Faiqah; Nadirah Rasyid Ridha
Journal Health & Science : Gorontalo Journal Health and Science Community Vol 7, No 4 (2023): OKTOBER: JOURNAL HEALTH AND SCIENCE : GORONTALO JOURNAL HEALTH AND SCIENCE COMMU
Publisher : Gorontalo State University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35971/gojhes.v7i4.20751

Abstract

Non-Hodgkin’s Lymphoma (NHL) is a large group of malignant neoplasms originating in the lymph nodes and extra nodes of lymphoid tissues. This kind of malignancy is quite common in the world with 3% of all cancer cases. In Indonesia, NHL is the 6th most common cancer and is the third most rapidly progressive cancer after melanoma and lung cancer. The novelty in this study is diffuse large cell non hodgkin lymphoma at retrobular occulus sinistra mass. A 15-years-old boy came with complaints of a protruding left eye since 2 months ago, begin with reddish eyes which gradually enlarged and decrease of visual function. Biopsy confirmed the diagnose as a stage 2 non-Hodgkin's lymphoma with Diffuse large cells. This patient underwent a chemotherapy procedure according to the non-Hodgkin's lymphoma’s protocol for 1 year that turn out in decrease of tumor progression and good result of the chemotherapy. A case of retrobulbar mass occulus sinistra et causa non-Hodgkin's lymphoma in a 15 year old boy. Diagnose is based on history, physical examination, laboratory tests and biopsy. Treatment of this patient using chemotherapy regimens according to the non-Hodgkin's lymphoma protocol.
Co-Authors Nadirah Rasyid Ridha